Medical Tech Fears Labor's Tax Plan Hits R&D Startups
Sydney, NSW – Australia's medical technology sector is voicing concerns over Labor's proposed overhaul of capital gains tax (CGT), warning that new restrictions on research and development (R&D) tax refunds could severely impact health startups.
Industry representatives are arguing that the changes, part of the government's broader CGT reforms, will disincentivise investment in early-stage medical technology companies. The proposed reforms limit the amount of R&D tax refunds available, particularly affecting companies that haven't yet turned a profit but are heavily investing in innovation.
Medical technology companies rely heavily on R&D tax incentives to fund their crucial early-stage research and development activities. These incentives allow them to offset some of the substantial costs associated with bringing new medical devices and treatments to market. The potential reduction in these refunds is expected to make it more difficult for these companies to secure funding and compete globally.
The sector highlights the importance of a vibrant medical technology ecosystem for Australia's healthcare system and economic growth. Startups in this area often develop cutting-edge solutions that improve patient outcomes and address unmet medical needs. Limiting their access to crucial tax support could stifle innovation and lead to a decline in investment in the sector.
Labor has stated its intention to reform the R&D tax incentive program to ensure it targets genuine research activity and delivers value for taxpayers. However, the medical technology sector maintains that the proposed changes are overly broad and will disproportionately harm small, innovative companies. Discussions are ongoing between the government and industry stakeholders to find a solution that supports both fiscal responsibility and continued investment in medical innovation.
